PMID- 38444590
OWN - NLM
STAT- MEDLINE
DCOM- 20240307
LR  - 20240312
IS  - 1664-2392 (Print)
IS  - 1664-2392 (Electronic)
IS  - 1664-2392 (Linking)
VI  - 15
DP  - 2024
TI  - Prevalence and clinical correlates of hyperhomocysteinemia in Chinese urban 
      population with hypertension.
PG  - 1369997
LID - 10.3389/fendo.2024.1369997 [doi]
LID - 1369997
AB  - CONTEXT: The coexistence of hypertension and elevated homocysteine (Hcy) levels 
      has a mutually reinforcing impact on the susceptibility to cardio-cerebrovascular 
      disease. OBJECTIVE: The aim was to assess the prevalence, clinical correlation, 
      and demographic characteristics of hyperhomocysteinemia (HHcy) within the Chinese 
      urban population with hypertension. METHODS: A cohort of 473 individuals with 
      hypertension were selected from four communities in Shenzhen, China. Demographic 
      attributes, clinical profiles, and lifestyle behaviors were gathered and compared 
      between individuals with and without HHcy. A logistic regression model was 
      employed to examine potential factors associated with the prevalence of HHcy. 
      Correlation between Hcy levels and clinical characteristics was assessed through 
      multiple linear regression analysis. RESULTS: The prevalence of HHcy in the 
      population with hypertension was 31.3%. In comparison to individuals without 
      HHcy, those with HHcy exhibited a higher proportion of males, a higher prevalence 
      of smoking and alcohol consumption, and a higher proportion of cases with the 
      homozygous (TT) genotype at the MTHFR C677T polymorphism. Moreover, individuals 
      with HHcy had lower levels of folic acid (FA), and lower fruit and vitamin B12 
      intake. Furthermore, the risk factors for HHcy were male (B = 1.430, OR = 4.179) 
      and MTHFR (TT) (B = 1.086, OR = 2.961). In addition, the multiple linear 
      regression analysis revealed a significant association between Hcy levels and 
      gender (B = -2.784, P = 0.004), MTHFR genotypes (B = 1.410, P = 0.005), and FA 
      levels (B = -0.136, P = 0.030). CONCLUSION: The high prevalence of HHcy among 
      hypertensive patients in this Chinese urban population underscores the necessity 
      for interventions targeting modifiable risk factors such as dietary choices and 
      lifestyle practices.
CI  - Copyright (c) 2024 Xu, Feng, Zhang, Li, Chi and Ren.
FAU - Xu, Yayun
AU  - Xu Y
AD  - Department of Neurology, The First Affiliated Hospital of Shenzhen University, 
      Shenzhen Second People's Hospital, Shenzhen, China.
FAU - Feng, Haixing
AU  - Feng H
AD  - Department of Neurology, The First Affiliated Hospital of Shenzhen University, 
      Shenzhen Second People's Hospital, Shenzhen, China.
FAU - Zhang, Liping
AU  - Zhang L
AD  - Department of Neurology, The First Affiliated Hospital of Shenzhen University, 
      Shenzhen Second People's Hospital, Shenzhen, China.
FAU - Li, Yanlei
AU  - Li Y
AD  - Department of Neurology, The First Affiliated Hospital of Shenzhen University, 
      Shenzhen Second People's Hospital, Shenzhen, China.
FAU - Chi, Feng
AU  - Chi F
AD  - Department of Neurology, The First Affiliated Hospital of Shenzhen University, 
      Shenzhen Second People's Hospital, Shenzhen, China.
FAU - Ren, Lijie
AU  - Ren L
AD  - Department of Neurology, The First Affiliated Hospital of Shenzhen University, 
      Shenzhen Second People's Hospital, Shenzhen, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20240220
PL  - Switzerland
TA  - Front Endocrinol (Lausanne)
JT  - Frontiers in endocrinology
JID - 101555782
SB  - IM
MH  - Humans
MH  - Male
MH  - Female
MH  - Urban Population
MH  - *Hyperhomocysteinemia/complications/epidemiology
MH  - Prevalence
MH  - *Hypertension/epidemiology
MH  - China/epidemiology
PMC - PMC10912325
OTO - NOTNLM
OT  - clinical correlates
OT  - hyperhomocysteinemia
OT  - hypertension
OT  - prevalence
OT  - urban
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2024/03/06 06:42
MHDA- 2024/03/07 06:43
PMCR- 2024/01/01
CRDT- 2024/03/06 03:49
PHST- 2024/01/13 00:00 [received]
PHST- 2024/02/05 00:00 [accepted]
PHST- 2024/03/07 06:43 [medline]
PHST- 2024/03/06 06:42 [pubmed]
PHST- 2024/03/06 03:49 [entrez]
PHST- 2024/01/01 00:00 [pmc-release]
AID - 10.3389/fendo.2024.1369997 [doi]
PST - epublish
SO  - Front Endocrinol (Lausanne). 2024 Feb 20;15:1369997. doi: 
      10.3389/fendo.2024.1369997. eCollection 2024.